Si Liangguo, Zhang Wenping, Jiang Haifeng, Ma Haiqiang, Ma Xu, Zhao Peijie, Sun Huanhuan, Yang Zhipeng, Qiao Zewen
School of Clinical Medicine, Ningxia Medical University , 750004, Yinchuan, China.
General Hospital of Ningxia Medical University, 750004, Yinchuan, China.
Sci Rep. 2025 Aug 21;15(1):30694. doi: 10.1038/s41598-025-14824-0.
Traumatic osteomyelitis (TO) treatment remains challenging due to biofilm formation and poor antibiotic penetration. We developed poly(lactic-co-glycolic acid) (PLGA) microspheres co-loaded with moxifloxacin/rifampicin (M/R-P) to address these limitations. Key findings: In vitro: The microspheres showed (1) no cytotoxicity (CCK-8 assay; live/dead staining; cytoskeletal staining; SEM visualization), and (2) no inhibition of osteogenic potential (ALP activity).In vivo: M/R-P microspheres significantly reduced MRSA burden ( 8 ± 3 × 10³ CFU/g) compared to debridement-only controls (3143 ± 727 × 10³ CFU/g; p < 0.0001), and near-complete infection resolution (histopathology). Conclusion: These results demonstrate that the M/R-P microspheres possess excellent safety profiles, favorable cytocompatibility, and remarkable antibacterial efficacy. The findings confirm the feasibility of our innovative approach using PLGA as a drug delivery carrier for localized antibiotic therapy in chronic osteomyelitis treatment, achieved through technological optimization for combined antibiotic administration. This provides a novel strategic direction for ultimately overcoming the clinical challenge of traumatic osteomyelitis.
由于生物膜形成和抗生素渗透性差，创伤性骨髓炎（TO）的治疗仍然具有挑战性。我们开发了载有莫西沙星/利福平（M/R-P）的聚乳酸-羟基乙酸共聚物（PLGA）微球来解决这些局限性。主要发现：体外：微球显示（1）无细胞毒性（CCK-8 检测；活/死染色；细胞骨架染色；扫描电子显微镜观察），以及（2）无抑制成骨潜能（碱性磷酸酶活性）。体内：与仅清创对照组（3143±727×10³CFU/g；p<0.0001）相比，M/R-P 微球显著降低了耐甲氧西林金黄色葡萄球菌负担（8±3×10³CFU/g），且感染几乎完全消退（组织病理学）。结论：这些结果表明，M/R-P 微球具有优异的安全性、良好的细胞相容性和显著的抗菌疗效。这些发现证实了我们创新方法的可行性，即通过技术优化联合使用抗生素，将 PLGA 作为慢性骨髓炎局部抗生素治疗的药物递送载体。这为最终克服创伤性骨髓炎的临床挑战提供了一个新的战略方向。
